Medicago announces collaboration with Acambis to evaluate vaccine production using Proficia(TM)

Sep 27, 2005, 01:00 ET from MEDICAGO

    QUEBEC CITY, QC, Sept. 27 /PRNewswire/ - Medicago, Inc. announced today
 the signature of an agreement with Acambis Inc., the US subsidiary of Acambis
 plc (LSE: ACM; NASDAQ:   ACAM), to evaluate the expression of recombinant
 vaccines using Medicago's plant-based Proficia(TM) system.
     Medicago will receive milestone payments from Acambis to assess the
 feasibility of using Medicago's Proficia(TM) Protein Technology for the
 production of vaccines.
     Medicago expects to announce further agreements in the area of vaccine
 development and manufacturing.
     Mr. Andy Sheldon, Medicago's President and Chief Executive Officer, said:
 "We believe that our Proficia(TM) technology presents competitive advantages
 over traditional vaccine manufacturing technologies for cost-effective
 production of recombinant vaccines. This agreement represents significant
 progress as Medicago enters the vaccine field."
     The efficiency and flexibility of Medicago's Proficia(TM) Protein
 Technology provides several advantages for vaccine manufacturing compared to
 cell culture and other biological expression systems: fast development time-
 lines and scale-up, contained and controlled manufacturing, consistent product
 quality, reduced contamination risk, lower production costs, flexibility of
 timing and reduced capital investments, for the cost-efficient production of
 biopharmaceuticals.
 
     About Medicago:
 
     Medicago has developed a breakthrough therapeutic protein manufacturing
 system, Proficia(TM), that can greatly improve the cost and accessibility of
 today's emerging biotherapeutics for both partners and patients. Medicago's
 safe and versatile Proficia(TM) system is fuelling multiple product
 developments programs for biotechnology and pharmaceutical partners as well as
 the company's own proprietary pipeline of products.
 
 

SOURCE MEDICAGO
    QUEBEC CITY, QC, Sept. 27 /PRNewswire/ - Medicago, Inc. announced today
 the signature of an agreement with Acambis Inc., the US subsidiary of Acambis
 plc (LSE: ACM; NASDAQ:   ACAM), to evaluate the expression of recombinant
 vaccines using Medicago's plant-based Proficia(TM) system.
     Medicago will receive milestone payments from Acambis to assess the
 feasibility of using Medicago's Proficia(TM) Protein Technology for the
 production of vaccines.
     Medicago expects to announce further agreements in the area of vaccine
 development and manufacturing.
     Mr. Andy Sheldon, Medicago's President and Chief Executive Officer, said:
 "We believe that our Proficia(TM) technology presents competitive advantages
 over traditional vaccine manufacturing technologies for cost-effective
 production of recombinant vaccines. This agreement represents significant
 progress as Medicago enters the vaccine field."
     The efficiency and flexibility of Medicago's Proficia(TM) Protein
 Technology provides several advantages for vaccine manufacturing compared to
 cell culture and other biological expression systems: fast development time-
 lines and scale-up, contained and controlled manufacturing, consistent product
 quality, reduced contamination risk, lower production costs, flexibility of
 timing and reduced capital investments, for the cost-efficient production of
 biopharmaceuticals.
 
     About Medicago:
 
     Medicago has developed a breakthrough therapeutic protein manufacturing
 system, Proficia(TM), that can greatly improve the cost and accessibility of
 today's emerging biotherapeutics for both partners and patients. Medicago's
 safe and versatile Proficia(TM) system is fuelling multiple product
 developments programs for biotechnology and pharmaceutical partners as well as
 the company's own proprietary pipeline of products.
 
 SOURCE  MEDICAGO